Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV:
LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech
company that leverages advancements in science and technology to
build breakthrough ventures that transform human wellness, is
pleased to announce that its U.S. biosciences subsidiary Mikra
Cellular Sciences Inc. ("Mikra") is preparing a large order of
single dose sample packets of
FOCUS for use in
upcoming promotions, including events featuring six time MLB
All-Star, three time Silver Slugger and Olympic medal winner Jose
Bautista. Mikra’s new product combines a precision blend of
citicoline, tyrosine and pure lion's mane mushroom to deliver
improved memory, total concentration and faster cognition without
any caffeine or stimulants.
FOCUS is anticipated
to launch in September.
“We are working to ensure that the
FOCUS launch will be different from any previous
Mikra new product introduction,” said Andrea Judge, CEO of Mikra.
“We want as many potential customers as possible to experience
firsthand the difference that FOCUS can make in
their day, so we plan to distribute samples widely and maximize our
exposure to the market. We will have a great deal more to announce
shortly.”
FOCUS combines the clinically
studied neuroprotective and cognition-enhancing effects of pure
citicoline with the performance-preserving and enhancing effects of
tyrosine and pure lion’s mane mushroom.
A systematic review of the medical use of
citicoline published in the Swiss journal Nutrients found:
“...In research based
on animals and humans, it was proved that citicoline is beneficial
in the regeneration of neurons, can increase levels of
neurotransmitters, and has a positive impact on cognitive
functions.”1
A Mt. Sinai Hospital clinical abstract on the medical use of
tyrosine reported:
“...Researchers
believe that, under stress, the body isn't able to make enough
tyrosine from phenylalanine. Some animal and human studies suggest
that tyrosine supplements may help improve memory and performance
under psychological stress... One study suggests that taking
tyrosine may help you be more alert after sleep deprivation.”2
Finally, a landmark Japanese randomized control
trial of lion’s mane mushroom demonstrated:
“MMSE [Mini Mental
State Examination] alone showed that oral intake of H. erinaceus
significantly improved cognitive functions and prevented
deterioration. We speculate that various chemical compounds,
including hericenones, in the mushroom have multiple effects to the
brain neural networks and improve cognitive functions.”3
FOCUS features a proprietary
precisely dosed blend of citicoline, tyrosine and pure lion's mane
mushroom as its primary active ingredients. All three have been
extensively studied and convincingly found to support enhanced
focus, improved memory and clearer cognition in published,
peer-reviewed clinical research.
Mikra is pushing biosciences beyond the expected
with the belief that it is possible to add more active, vigorous,
enjoyable, and valuable years to your life through protecting and
maintaining your cellular health.
Lifeist is committed to bringing natural
products backed by real science to market and looks forward to
reaching many more customers with new products in 2024 and
beyond.
About Lifeist Wellness Inc.
Sitting at the forefront of the post-pandemic
wellness revolution, Lifeist leverages advancements in science and
technology to build breakthrough companies that transform human
wellness. Portfolio business units include: Mikra, a biosciences
and consumer wellness company developing and selling innovative
products for cellular health; and CannMart, which operates a B2B
wholesale distribution business facilitating recreational cannabis
sales to Canadian provincial government control boards including
for CannMart Labs, a BHO extraction facility producing high margin
cannabis 2.0 products.
Information on Lifeist and its businesses can be
accessed through the links below:
www.lifeist.com https://wearemikra.com/
https://cannmart.com
Contact: Meni MorimCEOLifeist
Wellness Inc.Ph: 647-362-0390 Email: ir@lifeist.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release or has in any way approved
or disapproved of the contents of this press release.
Forward Looking Information
This news release contains “forward-looking
information” within the meaning of applicable securities laws. All
statements contained herein that are not historical in nature
contain forward-looking information. Forward-looking information
can be identified by words or phrases such as “may”, “expect”,
“likely”, “should”, “would”, “plan”, “anticipate”, “intend”,
“potential”, “proposed”, “estimate”, “believe” or the negative of
these terms, or other similar words, expressions and grammatical
variations thereof, or statements that certain events or conditions
“may” or “will” happen.
The forward-looking information contained
herein, including, without limitation, statements related to the
anticipated delivery of FOCUS to customers at the
end of the third quarter of this year and expectations relating to
Mikra’s future introduction of new products and reaching additional
customers in 2024, are made as of the date of this news release and
are based on assumptions management believed to be reasonable at
the time such statements were made, including without limitation,
expectations that the manufacturing of FOCUS is
successfully completed in a timely manner, the effectiveness and
benefits of FOCUS are as anticipated, its
expectation that the nutraceutical market will develop as currently
anticipated, the nutraceutical market will continue to be a
multi-billion dollar high-margin market, the introduction of new
products and brands will generate additional revenue, expectations
that FOCUS and other new nutraceutical products to
be developed by Mikra will gain market acceptance along with the
expansion of the market for nutraceutical products, as well as
other considerations that are believed to be appropriate in the
circumstances. While we consider these assumptions to be reasonable
based on information currently available to management, there is no
assurance that such expectations will prove to be correct. By its
nature, forward-looking information is subject to inherent risks
and uncertainties that may be general or specific and which give
rise to the possibility that expectations, forecasts, predictions,
projections or conclusions will not prove to be accurate, that
assumptions may not be correct, and that objectives, strategic
goals and priorities will not be achieved. A variety of factors,
including known and unknown risks, many of which are beyond our
control, could cause actual results to differ materially from the
forward-looking information in this news release. Such factors
include, without limitation: unforeseen delays in the manufacturing
and/or sale of FOCUS, the inability of the Company
to develop Mikra’s business as anticipated, unanticipated changes
to current regulations that would adversely impact Mikra’s
business, unforeseen developments that would delay Mikra’s ability
to sell newly developed nutraceutical products, the risk that the
expected demand for nutraceutical products in general and those of
Mikra in particular does not develop as anticipated and risks
relating to the Company’s ability to execute its business strategy
and the benefits realizable therefrom. Additional risk factors can
also be found in the Company’s current MD&A filed under the
Company’s SEDAR+ profile at www.sedarplus.ca. Readers are cautioned
not to put undue reliance on forward-looking information. The
Company undertakes no obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable law. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement.
______________________________________1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601330/2
https://www.mountsinai.org/health-library/supplement/tyrosine3
https://pubmed.ncbi.nlm.nih.gov/31413233/
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/45c22d48-e21b-421d-aded-fc62c0a8ca46
Source: Lifeist Wellness Inc.
Lifeist Wellness (TSXV:LFST)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Lifeist Wellness (TSXV:LFST)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024